Article
Results of a controlled Phase I/II study show that the bioerodable, sustained-release,dexamethasone implant (Posurdex, Allergan) results in a statistically significantincrease in ETDRS standardized visual acuity in eyes with persistent cystoidmacular edema (CME), said Mark S. Blumenkranz, MD.